Failure of CDKN2A/B (INK4A/B–ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL
CG Mullighan, RT Williams, JR Downing… - Genes & …, 2008 - genesdev.cshlp.org
CG Mullighan, RT Williams, JR Downing, CJ Sherr
Genes & development, 2008•genesdev.cshlp.orgDeletions of the CDKN2A/B tumor suppressor locus and of the IKAROS and PAX5 genes
that promote B-lineage development occur frequently in lymphoid, but not myeloid
leukemias initiated by the BCR-ABL tyrosine kinase. Why is this the case, and how do these
genetic lesions contribute to an aggressive disease that fails to durably respond to targeted
kinase inhibitors?
that promote B-lineage development occur frequently in lymphoid, but not myeloid
leukemias initiated by the BCR-ABL tyrosine kinase. Why is this the case, and how do these
genetic lesions contribute to an aggressive disease that fails to durably respond to targeted
kinase inhibitors?
Deletions of the CDKN2A/B tumor suppressor locus and of the IKAROS and PAX5 genes that promote B-lineage development occur frequently in lymphoid, but not myeloid leukemias initiated by the BCR-ABL tyrosine kinase. Why is this the case, and how do these genetic lesions contribute to an aggressive disease that fails to durably respond to targeted kinase inhibitors?
genesdev.cshlp.org